本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of 65 kinds of monkeypox antibodies, antigens and cell lines, which has won wide praise from the public. Monkeypox human antibody, as the core product launched by Sanyou Bio has excellent affinity activity and complete data verification, which can be used not only for the development of therapeutics, but also for structure analysis and bispecific antibody research, as well as diagnostic reagents and scientific research. Except for monkeypox human antibody, the product line Sanyou Bio launched this time features 65 items across three main categories: 26 natural epitope antigens, 28 high-affinity, high-specificity monoclonal antibodies and 11 overexpression cell lines. These products target multiple key sites on the surface of monkeypox virus, including A29L, M1R, H3L, E8L, A35R, B6R, and critical sites such as A28L, A30L, B21R, L1R and I1L, which are vital for viral infection and assembly. All monkeypox products are subject to rigorous data verification. Developed using Sanyou Bio's proprietary "over-trillion innovative antibody discovery" platform, the monoclonal antibodies span multiple species, including fully human, nano, and mouse antibodies. These antibodies are essential for therapeutic drug development, with high-affinity nano antibodies being particularly valuable for structural analysis and bispecific research. Additionally, the entire range of antibodies, natural epitope antigens, and overexpression cell lines can be utilized in diagnostic reagents and scientific research. Through activities such as free application of monkeypox virus full range of antigens and antibodies trial kits, Sanyou Bio has successfully helped global customers to facilitate research in different directions such as vaccines, drugs and diagnostic reagents, and accelerate the exploration of the unknown world of monkeypox virus. Dr. Lang Guojun, CEO of Sanyou Biology, emphasized the great breakthrough in monkeypox antibodies, especially monkeypox human antibodies, Sanyou Bio aims to strengthen the development of vaccines, therapeutics, diagnostic tools and research initiatives, furthering its commitment to global public health. About Sanyou Bio Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS", to accomplish the mission "to make the R&D easy for innovative biologics". Sanyou has established an integrated innovative biologic drug R&D laboratory with advanced facilities, and has a professional team with the majority holding a Ph.D. or master degree. Sanyou has built three industry-leading innovative technology platforms featured by "super-trillion, integration, and intelligence" , which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform, and supported by platforms of material preparation, biologics discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc. Sanyou's business network has expanded to all parts of the world, including Asia, US and Europe, and established branches in Boston, Philadelphia, San Diego and London. Sanyou has established friendly business relationships with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide. Sanyou received National-level certification as a high-tech enterprise and a Specialized and Sophisticated enterprise, and passed the ISO9001 quality assurance certification and GB/T intellectual property management system certification.
隨著蘋果新機iPhone 16系列即將在下周登場，非蘋陣營智慧手機壓力不小，各大品牌持續推出降價優惠，根據傑昇通信統計8月門市手機銷售價格資料，公佈2024年8月降價手機TOP 15排行榜顯示，單機降幅在2%~23%不等，整體總降幅範圍則在7%~28%之間；果粉們關心是否有iPhone降價機型進榜，傑昇通信表示，在新機定價未明朗前，不排除這波價平量縮的現象會持續到新機上市；而本月共七個品牌進榜，消費者可選擇的機型更多，像是降價冠軍moto Razr 50降價高達5千元、三星Galaxy S24 Ultra（12GB/256GB）累積總降價金額達12,110元，降幅顯著正是入手的好時機。 iPhone 16系列發表進入倒數，全台最大通訊連鎖門市─傑昇通信分析，八月整體手機市場受新機效益加持，各品牌在市面上流通的機型不得不降價搏眼球，雖然父親節、七夕情人節帶來的買氣不如預期，然而品牌業者加上通路商，共同釋出的利多，還是吸引不少消費者換機；不過，期待iPhone 15系列大降價的果粉希望落空，八月沒有任何一款iPhone機型進榜，顯見不只果粉出手保守，各通路在新機上市前，價格也有所停滯。 八月降價榜一共有7個品牌，舉凡當前降價的旗艦機，甚至五千出頭的高性價比機型都有，相當值得做為換機依據。其中更以新一代摺疊Motorola Razr 50強降五千、月降幅達23%居雙冠王，傑昇通信指出，Razr 50系列上市才一個多月，包含Razr 50 Ultra也在降價榜前五名，主要是近期摺疊手機市場競爭加劇，品牌與各通路平台有較深的專案合作，因此在價格方面的彈性較大，才有比較多降價空間吸引消費者目光。 近期隨著Galaxy S25系列的曝光，當前熱銷旗艦三星Galaxy S24 Ultra（12GB/256GB）也開始有甜甜價，搭載高倍數長焦鏡頭的Galaxy S24 Ultra，還擁有可清晰捕捉低光源的拍攝能力，具備 IP68 防塵防水等級，最引人注目的功能是強大的「Galaxy AI」，以及承諾七年內不斷更新，上市至今總降幅達28%、總降價金額累積12,110元最高，對預算有限又想擁有旗艦規格的消費者而言，此時入手旗艦機正是時候，建議民眾可趁通路打折買起來。 另一款則是累積總降幅近4成vivo V30e（8GB/256GB），有最新自拍神機之稱的V30e，延續V30系列引以為傲的「柔光人像3.0」技術，更配備5,000萬畫素超感光主鏡頭及搭載全台首發台積電（2330）4nm高通驍龍6 Gen 1旗艦處理器，內建5,500mAh電池續航，支援44W極速閃充，電池耐用度可至四年，6.78吋的螢幕，傑昇通信提到，現在空機價格萬元有找，算是同級規格內最低價，此時也是舊機價格最甜蜜的買點，完全可無痛入手。
NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the subject recruitment of CBL-514 Phase 2b study for Dercum's disease (CBL-0202 DD Phase 2b study, NCT06303570) has been initiated. The study results are anticipated in Q4 2025. CBL-0202DD study is a randomized, placebo-controlled Phase 2b study evaluating CBL-514 injection's efficacy and safety in treating Dercum's disease. A total of approximately 30 Dercum's disease subjects with four to ten painful lipomas will be enrolled in the study and randomized 1:1 into two groups to receive either CBL-514 or placebo once every 4 weeks for up to 5 treatments for each selected lipoma. The CBL-514 Phase 2b study features notable changes compared with the earlier Phase 2 study (CBL-0201DD, NCT05387733). While the Phase 2 study evaluated a 4-week treatment period with the primary efficacy endpoint designed to evaluate the change of lipoma dimensions, the Phase 2b study design extends the treatment period to 16 weeks, with lipoma size evaluated by ultrasound at an independent third-party facility during each visit from 4 weeks to 24 weeks after the first treatment. Additionally, the Phase 2b study design shifts the primary endpoint to the percentage of lipomas achieving a complete response compared to the placebo, providing a robust perspective on the drug's efficacy. With a longer treatment period, a larger subject population, and a more challenging primary endpoint, the CBL0202DD Phase 2b study represents a significant advancement in the pursuit of innovative treatments for Dercum's disease. Caliway will proceed with the CBL-514 Phase 3 Pivotal study IND for Dercum's disease as soon as the Phase 2b study results meet the efficacy endpoints. CBL-514 is the world's most advanced new drug in Dercum's disease clinical development and is also the only clinical drug with statistically significant efficacy. The previous CBL-0201DD Phase 2 study results have demonstrated significant painful lipoma size reduction with a pain reduction of 4.7 points. With the potential to become the first approved drug for Dercum's disease treatment, CBL-514 is currently the only new drug granted with both Orphan Drug Designation and Fast Track Designation for Dercum's disease treatment by the U.S. FDA, which will help accelerate its clinical development and increase the product value once it launches to the market. About Dercum's Disease Dercum's disease is a rare disorder that is characterized by the development of painful lipomas primarily located on the trunk region, and the extremities close to the trunk. The pain is chronic (>3 months), symmetrical, often disabling, and resistant to traditional analgesics. The etiology of Dercum's disease remains unknown. There is no approved drug nor recommended standard treatment for Dercum's disease yet. The current treatment options, including surgical removal, liposuction, electrotherapy, and inflammation inhibitors, are symptomatic, and the efficacies are limited with numerous adverse events. The clinical need for Dercum's disease remains unmet. According to the Global Dercum's Disease Market Research Report, the global Dercum's disease treatment market size in 2021 was $11.3 billion. With a compound annual growth rate (CAGR) of 6.76%, the global market of Dercum's disease treatment in 2030 is estimated to expand to $19.96 billion. About CBL-0202DD Phase 2b Study CBL-0202DD study (NCT06303570) is a randomized, placebo-controlled, Phase 2b study evaluating CBL-514 injection's efficacy and safety in treating Dercum's disease subjects. The study will enroll approximately 30 Dercum's disease subjects with four to ten painful lipomas and randomize them 1:1 into two groups to receive CBL-514 injection or placebo. Each subject will receive up to 5 courses of CBL-514 injection or placebo administered into selected lipomas once every 4 weeks for 16 weeks in total, and the injection volume per lipoma will be based on the lipoma size, determined by ultrasound. The efficacy of CBL-514 on each lipoma will be evaluated during each visit from 4 weeks to 24 weeks after the first treatment at an independent third-party facility. The primary endpoint is the percentage of lipomas with complete response compared to placebo. The secondary endpoints include the percentage of lipomas with partial response compared to placebo, the duration of complete response/partial response lasting on the lipomas compared to placebo, the percentage change in lipoma volume compared to placebo, and the change of pain scores on the lipomas compared to placebo. About CBL-514 CBL-514, a potentially first-in-class small-molecule drug, is a lipolysis injection that can induce adipocyte apoptosis to reduce subcutaneous adiposity in treatment areas without causing any systematic side effects on the central nervous system, cardiovascular system, and respiratory system. Caliway's preclinical studies have shown that CBL-514 upregulates the apoptosis mediators caspase 3 and Bax/Bcl-2 ratio and then induces adipocyte apoptosis in vivo and in vitro. Caliway has completed CBL-0201DD, a Phase 2 study (NCT05387733) to evaluate the efficacy and safety of CBL-514 in treating Dercum's disease. The study results showed that after CBL-514 treatment, 64.5% of painful lipomas showed a dimensional reduction of more than 50%, and 38.7% of painful lipomas showed complete clearance, with a pain reduction of 4.7 points. In addition, CBL-0202DD, a Phase 2b IND (NCT06303570), has been approved by the U.S. FDA in January 2024, with subject recruitment initiating in August 2024 and the study results are anticipated in Q4 2025. About Caliway Biopharmaceuticals Caliway Biopharmaceuticals (Caliway) is a Taiwan-headquartered, clinical-stage biopharmaceutical company driven to breakthrough drug discovery of novel small-molecule therapeutics. Listed on the emerging stock market in Taiwan (TPEX-6919), Caliway aims to become an innovative pharmaceutical leader in aesthetic medicine and other diseases. Disclaimer This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change. For additional contact: info@caliway.com.tw
Sublingual NAD+ is the new gold standard for daily NAD+ supplementation, without the need for precursors SINGAPORE, Sept. 2, 2024 /PRNewswire/ -- iX Biopharma (the "Company"), a specialty pharmaceutical company specializing in drug delivery systems and a leader in innovative healthspan nutraceuticals, has announced groundbreaking results from a pharmacokinetic study evaluating the sublingual absorption of a novel NAD+ wafer, SL-NAD+. This study is the first to provide compelling evidence that NAD+ can directly enter cells, offering a promising new approach to NAD+ supplementation. The study consisted of 3 parts: 2 single-dose PK studies and a multiple-dose PK study, conducted in 18 Sprague-Dawley rats, examining the plasma and red blood cell NAD+ levels following sublingual administration of NAD+. Assessment of NAD+ levels were done via the LC-MS/MS method, one of the most advanced and reliable methods to test for NAD+. The results revealed several important findings: First evidence of direct cellular entry: The study strongly suggests that NAD+ can be transported in and out of cells directly (NAD+ flux), most probably via connexin 43 hemichannels and other solute carrier channels. This is the first in-vivo study to provide evidence supporting this capability. Rapid sublingual absorption: Mean peak plasma concentration, a 2-fold increase in plasma NAD+ levels, was achieved within 10 minutes of dosing. This underscores the effectiveness of sublingual delivery through the mucosa. Significant bioavailability: The findings suggest a sublingual bioavailability of SL-NAD+ at 22% compared to intravenous (IV) administration. This provides a promising alternative to IV NAD+ therapy, with the potential for more convenient and sustained NAD+ delivery. Dr. Janakan Krishnarajah, Chief Operating Officer and Chief Medical Officer of iX Biopharma, said: "This study's findings provide strong evidence that our innovative sublingual freeze-dried technology delivers NAD+ rapidly into plasma and then directly into cells, challenging the previously held belief that its large size prevents cellular penetration. Along with the positive data from our recent human clinical study, this breakthrough positions direct NAD+ supplementation as the new gold standard for boosting NAD+ levels, removing the need for precursors." About NAD+ and SL-NAD+ NAD (nicotinamide adenine dinucleotide) is a critical molecule in our body responsible for vital cellular functions in the body. It is crucial for energy production, cellular metabolism, DNA repair, regulating sleep cycles and promoting healthy aging. NAD+ levels decrease as we age, with levels typically dropping to half by the time we reach 50. The decline in NAD+ levels with age is linked to various age-related health concerns and metabolic disorders. In recent years, NAD+ has become an important focus in scientific research on aging, with maintenance of adequate NAD+ levels being linked to healthy aging and longevity. Clinical trials have also been conducted to investigate the potential of NAD+ in treating various age-related diseases, such as Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease, neurodegenerative diseases like Parkinson's disease, cardiovascular and skeletal muscle diseases. Despite its potential, NAD+ has been challenging to utilise effectively, other than through IV. Alternative ways to boost NAD+ levels with NAD precursors, like NMN and NR, may be inefficient due to bioavailability and other issues, such as inefficient conversion to NAD+ due to age-related declines in enzyme activity. SL-NAD+ is a novel sublingual wafer that delivers NAD+ directly into the bloodstream, bypassing the digestive system to ensure higher bioavailability and significantly boosting intracellular NAD+ levels. The Company's proprietary freeze-drying process and patented wafer formulation stabilises NAD+ and delivers them as nanoparticles, ensuring rapid disintegration, release, and absorption through the sublingual mucosa. SL-NAD+ is available for purchase on https://entity-health.com/product/sl-nad/ and through select specialist clinics in Singapore. About iX Biopharma Ltd iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of pharmaceutical drugs and innovative nutraceuticals using novel, patent-protected formulations for sublingual delivery. iX Biopharma has developed a number of drug delivery platform technologies, including WaferiX, WaferlogiX and NADiX, which deliver small molecule and biologics sublingually via the mucosa for better absorption, faster onset of action and predictable effect. The drug delivery platforms are particularly useful for drug repurposing, where existing approved drugs are developed into new drugs targeting different indications or a different route of administration, at a lower development cost and risk. iX Biopharma's portfolio includes among others, ketamine, dexmedetomidine, medicinal cannabis and nutraceuticals designed to improve healthspan and longevity.
SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of a comprehensive product line targeting monkeypox, which includes antigens, monoclonal antibodies, and overexpression cell lines. This product line features 65 items across three main categories: 26 natural epitope antigens, 28 high-affinity, high-specificity monoclonal antibodies and 11 overexpression cell lines. These products target multiple key sites on the surface of monkeypox virus, including A29L, M1R, H3L, E8L, A35R, B6R, and critical sites such as A28L, A30L, B21R, L1R and I1L, which are vital for viral infection and assembly. Developed using Sanyou Bio's proprietary "over-trillion innovative antibody discovery" platform, the monoclonal antibodies span multiple species, including fully human, nano, and mouse antibodies. These antibodies are essential for therapeutic drug development, with high-affinity nano antibodies being particularly valuable for structural analysis and bispecific research. Additionally, the entire range of antibodies, natural epitope antigens, and overexpression cell lines can be utilized in diagnostic reagents and scientific research. Dr. Lang Guojun, CEO of Sanyou Bio, emphasized the company's rapid response capabilities, citing significant contributions during the COVID-19 pandemic. During that time, Sanyou Bio played a key role in the drug discovery and preclinical development of two innovative COVID-19 antibody therapies, which were published in leading journals such as Science and Cell Research, with related therapeutics advancing to clinical trials. With this new monkeypox product line, Sanyou Bio aims to strengthen the development of vaccines, therapeutics, diagnostic tools and research initiatives, furthering its commitment to global public health. About Sanyou Biopharmaceuticals Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS", to accomplish the mission "to make the R&D easy for innovative biologics". Sanyou has established an integrated innovative biologic drug R&D laboratory with advanced facilities, and has a professional team with the majority holding a Ph.D. or master degree. Sanyou has built three industry-leading innovative technology platforms featured by "super-trillion, integration, and intelligence" , which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform, and supported by platforms of material preparation, biologics discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc. Sanyou's business network has expanded to all parts of the world, including Asia, US and Europe, and established branches in Boston, Philadelphia, San Diego and London. Sanyou has established friendly business relationships with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide. Sanyou received National-level certification as a high-tech enterprise and a Specialized and Sophisticated enterprise, and passed the ISO9001 quality assurance certification and GB/T intellectual property management system certification.
台灣智慧手機市場2024年7月銷售數字揭曉，本月全台智慧手機銷售量達39.4萬台，較6月的40.2萬台微幅下降2%，但與去年同期的38.5萬台相比，則成長2%，市場表現趨於穩定；傑昇通信分析，隨著蘋果新品發布會倒數，市場觀望情緒加劇，競爭格局也隨之變化，受惠暑期換機需求及蘋果新機效應延後，三星在7月以29.2%的市占率再次奪冠，領先蘋果的27.2%，而第三至第五名的品牌分別為OPPO（16.1%）、vivo（8.5%）及Redmi（7.9%）。 台灣智慧型手機市場風向變遷，果粉觀望情緒短期內難以消退，非蘋陣營將持續受惠，全台最大連鎖通訊門市─傑昇通信分析，此次看似下滑的品牌市占率，實則銷量波動幅度縮小，市場正轉往穩定的過渡階段，加上暑期換機需求，安卓品牌大打價格戰，意外催生OPPO、vivo及紅米品牌銷量。 傑昇通信解讀品牌市占排行，蘋果在新機發表前的觀望效應顯著，導致部分消費者延後購機，影響了iPhone銷量的表現；相比之下，三星則抓住這一市場空檔，透過強勁的產品力與價格競爭策略，成功提升市場佔有率超車蘋果，連續兩個月成為台灣手機市場領導品牌；特別是三星Galaxy A55（8GB/256GB），該機型以單機銷量成長13%的優異成績，蟬聯本月銷售冠軍，甚至超越第二名iPhone 15（128GB）逾萬台，而旗艦機Galaxy S24+（12GB/256GB）也表現出色，單機銷量較上月成長10%。 儘管蘋果的市占率（27.2%）有所下滑，然而其在銷售額的市占率部分依然保持強勢，以49.3%占據市場半壁江山。傑昇通信表示，雖然蘋果的銷售量較上月下滑8%，前三名熱賣單機依舊以iPhone 15（128GB）奪下榜首，兩款主流規格iPhone 15 Pro Max（256GB）及iPhone 15 Pro（256GB）排名與上月相同，值得注意的是，iPhone 15 Pro（256GB）銷量較上月大幅下跌16%，顯示果粉對即將上市的iPhone 16期待與疑慮並存，這種趨勢可能會持續到9月新機上市之後。 此外，本月vivo也展現出強勁的市場表現，以8.5%的市占率脫穎而出。傑昇通信指出，異軍突起的vivo V30（12GB/512GB）在新機V40上市前進行的深度促銷活動，成功推升銷量25%，顯著提升品牌整體銷售量；同樣表現突出的還有OPPO，市占率達16.1%，其中Reno12 Pro（12GB/512GB）自6月底發表以來，7月銷量倍數成長，助推品牌整體銷售額提升26%，兩大品牌都是七月銷售量與銷售額市占成長最為顯著的MVP。
A12 藝術空間
vivo
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
